AppLovin remains a 'Hold' as valuation is still aggressive despite strong recent performance and EPS beats. APP's expansion into e-commerce and AI-driven creative tools strengthens its business mix ...

Lockheed Martin continues to underperform, with a decade of low growth, margin pressure, and a lackluster trajectory. Recent White House scrutiny on defense contractor capital allocation threatens LMT ...

Add Yahoo as a preferred source to see more of our stories on Google. There’s a scene in “28 Years Later: The Bone Temple,” Nia DaCosta’s quick-fire sequel to last year’s horror franchise returnee “28 ...

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ABLi will leverage the ability ...

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and ATLANTA and NEW ...

There’s a scene in “28 Years Later: The Bone Temple,” Nia DaCosta’s quick-fire sequel to last year’s horror franchise returnee “28 Years Later,” that’ll likely raise more than a few laughs in cinemas.